SOURCES SOUGHT
R -- Data Coordinating Center (DCC) for The Clinical Proteomics Tumor Analysis Consortium (CPTAC) Program - Sources Sought Notice Package
- Notice Date
- 1/6/2016
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- HHS-NIH-NCI-SBSS-TSB-67005-16
- Archive Date
- 1/28/2016
- Point of Contact
- Nicole Belanger, Phone: 301 624 8754
- E-Mail Address
-
belangern@mail.nih.gov
(belangern@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- DRAFT Statement of Work_CPTAC DCC Sources Sought_01-06-16 CPTAC DCC Sources Sought Notice_01-06-2016 (CPTAC) Program Introduction: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The NAICS code for this acquisition is 541990, which has a size standard of $15 million. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. As a result of this SBSS Notice, the NCI may issue a Request for Proposal (RFP). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Small Business Sources Sought Notice or the NCI’s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. A determination by the Government not to compete this requirement as a set-aside based upon responses to this Notice is solely within the discretion of the Government. Interested parties are expected to review this Notice and the draft Statement of Work (SOW) to familiarize themselves with the requirements of this project; failure to do so will be at your firm’s own risk. Background: The National Cancer Institute is expanding its basic and translational research programs that rely heavily on sufficient availability of high quality well annotated biospecimens suitable for concurrent use in proteomic and genomic studies. The National Cancer Institute’s (NCI) overarching goal with such programs is to improve the ability to diagnose, treat, and prevent cancer. The Clinical Proteomic Tumor Analysis Consortium (CPTAC), one such program, is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of proteomic and genomic technologies. NCI launched CPTAC as a technology assessment program in 2006. In its second phase, CPTAC provided proteomic analysis to selected biospecimens from The Cancer Genome Atlas (TCGA). Now in its third phase, CPTAC will expand the depth of analysis and breadth of tumor types to systematically explore the entire spectrum of proteomic and genomic changes involved in human cancer. Specifically, the project is designed to comprehensively analyze protein, RNA, and DNA sequences, DNA copy number changes, protein and transcription profiles, sequence variation, and sequence in both tumor tissue and case-matched germline DNA. The suite of analysis platforms will be applied to a common set of molecular analytes obtained from clinically annotated, high-quality, tumor biospecimens and case-matched nonmalignant tissue. More detailed information can be found at the project’s website: http://proteomics.cancer.gov. To successfully generate comprehensive data, CPTAC will need in excess of 4,000 biospecimens over the course of the project. During its second phase CPTAC generated 20 terabytes (TB) of data, spanning biospecimen information, patient information, and proteome, genome, exome and epigenetic data for both tumor and normal specimens per patient. The ability to ensure data completeness associated with each specimen required a coordinated effort across numerous institutions and information systems. This coordination will become increasingly difficult and important as the program triples the number of tumor types in the coming five (5) years. The purpose of the Data Coordinating Center (DCC) is to collect, analyze, review, store and distribute the data associated with CPTAC. The attached draft Statement of Work (SOW) document outlines the purpose, requirements and scope of the CPTAC DCC.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/HHS-NIH-NCI-SBSS-TSB-67005-16/listing.html)
- Place of Performance
- Address: Contractor's Facilities, United States
- Record
- SN03983890-W 20160108/160106234336-96599f8fdb81e402d65b3d9dcea67ab2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |